View in EDS HTML Full Text PDF Full Text

First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.

Saved in:
Bibliographic Details
Title: First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
Authors: Powderly JD 2nd; Carolina BioOncology Institute, Huntersville, NC 28078, United States., Gutierrez ME; Hackensack University Medical Center, Hackensack, NJ 07601, United States., Balmanoukian AS; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA 90025, United States., Hoyle PE; Incyte Corporation, Wilmington, DE 19803, United States., Dong Z; Incyte Corporation, Wilmington, DE 19803, United States., Cheng L; Incyte Corporation, Wilmington, DE 19803, United States., Chen X; Incyte Corporation, Wilmington, DE 19803, United States., Janik JE; Incyte Corporation, Wilmington, DE 19803, United States., Bourayou N; Incyte Biosciences International Sàrl, 1110 Morges, Switzerland., Hamid O; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA 90025, United States.
Source: The oncologist [Oncologist] 2025 Jul 04; Vol. 30 (7).
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40631774
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Powderly+JD+2nd%22">Powderly JD 2nd</searchLink>; Carolina BioOncology Institute, Huntersville, NC 28078, United States.<br /><searchLink fieldCode="AU" term="%22Gutierrez+ME%22">Gutierrez ME</searchLink>; Hackensack University Medical Center, Hackensack, NJ 07601, United States.<br /><searchLink fieldCode="AU" term="%22Balmanoukian+AS%22">Balmanoukian AS</searchLink>; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA 90025, United States.<br /><searchLink fieldCode="AU" term="%22Hoyle+PE%22">Hoyle PE</searchLink>; Incyte Corporation, Wilmington, DE 19803, United States.<br /><searchLink fieldCode="AU" term="%22Dong+Z%22">Dong Z</searchLink>; Incyte Corporation, Wilmington, DE 19803, United States.<br /><searchLink fieldCode="AU" term="%22Cheng+L%22">Cheng L</searchLink>; Incyte Corporation, Wilmington, DE 19803, United States.<br /><searchLink fieldCode="AU" term="%22Chen+X%22">Chen X</searchLink>; Incyte Corporation, Wilmington, DE 19803, United States.<br /><searchLink fieldCode="AU" term="%22Janik+JE%22">Janik JE</searchLink>; Incyte Corporation, Wilmington, DE 19803, United States.<br /><searchLink fieldCode="AU" term="%22Bourayou+N%22">Bourayou N</searchLink>; Incyte Biosciences International Sàrl, 1110 Morges, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hamid+O%22">Hamid O</searchLink>; The Angeles Clinic and Research Institute, a Cedars Sinai Affiliate, Los Angeles, CA 90025, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2025 Jul 04; Vol. 30 (7).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40631774
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyaf136
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Powderly JD 2nd
      – PersonEntity:
          Name:
            NameFull: Gutierrez ME
      – PersonEntity:
          Name:
            NameFull: Balmanoukian AS
      – PersonEntity:
          Name:
            NameFull: Hoyle PE
      – PersonEntity:
          Name:
            NameFull: Dong Z
      – PersonEntity:
          Name:
            NameFull: Cheng L
      – PersonEntity:
          Name:
            NameFull: Chen X
      – PersonEntity:
          Name:
            NameFull: Janik JE
      – PersonEntity:
          Name:
            NameFull: Bourayou N
      – PersonEntity:
          Name:
            NameFull: Hamid O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 07
              Text: 2025 Jul 04
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1